Gliomas in rodent whisker barrel cortex: a new tumor model

Sherburn, Eric W.; Wanebo, John E.; Kim, Paul; Song, Sheng‐Kwei; Chicoine, Michael R.; Woolsey, Thomas A.

doi:10.3171/jns.1999.91.5.0814

Cited by 16 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, the rapid growth rate of this DBT cell line would be unusual for human gliomas. We note that syngeneic intracranial implantation of the DBT mouse cell line in mice has been characterized as a laboratory model for glioblastoma, including rapid growth rate, hypercellularity, palisading necrosis, and immunoreactivity for GFAP (20, 21). We exploited the glioma intracranial implantation model as an effective system in which to assess intracranial tumor contrast enhancement after intravenous MRMC administration.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Albumin‐binding MR blood pool agents as MRI contrast agents in an intracranial mouse glioma model

Adzamli

Yablonskiy

Chicoine

et al. 2003

Magnetic Resonance in Med

Self Cite

View full text Add to dashboard Cite

The utility of clinical magnetic resonance contrast media (MRCM) in the evaluation of pathologies within the central nervous system (CNS) is well established (1-9). Bloodbrain-barrier (BBB) disruption in tumors and other lesions of the CNS is attributable to abnormal endothelial junctions, and is a key feature of the aggressive neovascular formations within malignant tumors. This characteristic of BBB disruption accounts for the increased enhancement of intracranial tumors on MRI after administration of MRCM, which is helpful in delineating tumor anatomy. For gliomas, increased enhancement is suggestive, although not absolutely indicative, of an increased histological grade of malignancy. Degrees of tumor malignancy previously have been assessed in animal models using covalently Gd-conjugated macromolecule-based MRCM as MRI signal enhancers (3-6). However, these covalently-bound Gd-macromolecules have not been studied in clinical trials in humans. Hence, the available low-molecular-weight extracellular MRCM are now exploited under dynamic protocols for tumor assessment (7-9). These agents extravasate into extracellular space throughout non-CNS tissues, and thus present a limited time window at high concentration for the detection of CNS tumors. Despite successes achieved with the extracellular agents to date, the need for intravascular agents that would extravasate only in the face of BBB disruption continues to be advocated as a next step in improving the diagnostic utility of these and related techniques (10,11).Noncovalent albumin-binding Gd-chelates represent a new class of agents. These agents, unlike the covalently bound Gd-macromolecules, are small chelates with side chains that undergo reversible noncovalent interactions with circulating albumin (12,13). The bound form (the dominant species, with a Ͼ10-fold signal-enhancing potential) assumes the macromolecular attributes of albumin and remains intravascular, while the nonbound minor component (with the low relaxivity typical of small Gdchelates) is free and extravasates. MP-2269 (Mallinckrodt, Inc., St. Louis, MO) is an experimental monomeric Gd-DTPA-derived blood pool agent with a molecular weight of 1179 g/mol. It is the Gd complex of 4-pentylbicyclo-

show abstract

Section: Discussionmentioning

confidence: 99%

“…Cell cultures were performed as previously described (17–20). Female BALB/cAnNCrlBr mice (15–20 g; Charles River Labs, Wilmington, MA) were anesthetized with an intraperitoneal administration of a ketamine/xylazine mixture (87 mg/kg ketamine and 13 mg/kg xylazine).…”

Section: Methodsmentioning

confidence: 99%

Albumin‐binding MR blood pool agents as MRI contrast agents in an intracranial mouse glioma model

Adzamli

Yablonskiy

Chicoine

et al. 2003

Magnetic Resonance in Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…0.5-0.6 mCi of 131 I-SIP(G11) was injected i.v. in rats bearing an orthotopic brain tumor, C6 malignant glioma (Sherburn et al, 1999). To assess the targeting performance of the iodinated antibody G11 autoradiography analysis of brain sections was performed 24 h after injection.…”

Section: Cloning Expression and Purification Of Scfv(g11)-il2mentioning

confidence: 99%

Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo

Silacci

Brack

Späth

et al. 2006

Protein Engineering Design and Selection

View full text Add to dashboard Cite

We had previously reported that splice isoforms of tenascin-C containing the extra-domain C are virtually absent in normal adult tissues but are highly abundant in high-grade astrocytomas, with a prominent peri-vascular pattern of expression. We now report that the extra-domain C of tenascin-C is strongly expressed in the majority of lung cancers, with a vascular and stromal pattern of expression. Using antibody phage technology, we have generated a human monoclonal antibody (G11), with a dissociation constant K(D) = 4.2 nM for the human domain C. The G11 antibody, expressed in scFv and in mini-antibody (SIP) format, as well as a scFv-interleukin-2 fusion protein, was then characterized in quantitative biodistribution studies using mice grafted subcutaneously with U87 gliomas, revealing a selective tumor uptake, with tumor/blood ratios up to 11.8:1 at 24 h. A radioiodinated preparation of SIP(G11) was also investigated in a double tracer study using an orthotopic rat glioma model, confirming the antibody's ability to preferentially localize at the tumor site, with tumor/brain ratios superior to the ones observed with (18)F-fluorodeoxyglucose. These tumor-targeting properties, together with the strong immunohistochemical staining of human tumor sections, indicate that the G11 antibody may be used as a portable targeting moiety for the selective delivery of imaging and therapeutic agents to gliomas and lung tumors.

show abstract

“…Herein, this focal delayed radiation injury model is combined with a well-validated intracerebral glioma model utilizing the murine astrocytoma DBT cell line (24,25). Since the cell line is murine in origin, immunocompetent mice can advantageously be employed to generate a more accurate and complete representation of the irradiated glioma model.…”

Section: Introductionmentioning

confidence: 99%

Toward Distinguishing Recurrent Tumor From Radiation Necrosis: DWI and MTC in a Gamma Knife–Irradiated Mouse Glioma Model

Pérez-Torres

Engelbach

Cates

et al. 2014

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Purpose Accurate non-invasive diagnosis is vital for effective treatment planning. Presently, standard anatomical MRI is incapable of differentiating recurring tumor from delayed radiation injury, as both lesions are hyperintense in both post-contrast T1- and T2-weighted images. Further studies are therefore necessary to identify an MRI paradigm that can differentially diagnose these pathologies. Mouse glioma and radiation injury models provide a powerful platform for this purpose. Methods and Materials Two MRI contrasts that are widely employed in the clinic were chosen for application with a glioma/radiation-injury model: diffusion weighted imaging, from which the apparent diffusion coefficient (ADC) is obtained, and magnetization transfer contrast, from which the magnetization transfer ratio (MTR) is obtained. These metrics were evaluated longitudinally, first in each lesion type alone – glioma vs. irradiation - and then in a combined irradiated glioma model. Results MTR was found to be consistently decreased in all lesions compared to nonlesion brain tissue (contralateral hemisphere), with limited specificity between lesion types. In contrast, ADC, though less sensitive to the presence of pathology, was increased in radiation injury and decreased in tumors. In the irradiated glioma model, ADC also increased immediately after irradiation, but decreased as the tumor regrew. Conclusions ADC is a better metric than MTR for differentiating glioma from radiation injury. However, MTR was more sensitive to both tumor and radiation injury than ADC, suggesting a possible role in detecting lesions that do not enhance strongly on T1-weighted images.

show abstract

Gliomas in rodent whisker barrel cortex: a new tumor model

Cited by 16 publications

References 34 publications

Albumin‐binding MR blood pool agents as MRI contrast agents in an intracranial mouse glioma model

Albumin‐binding MR blood pool agents as MRI contrast agents in an intracranial mouse glioma model

Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo

Toward Distinguishing Recurrent Tumor From Radiation Necrosis: DWI and MTC in a Gamma Knife–Irradiated Mouse Glioma Model

Contact Info

Product

Resources

About